Allogene therapeutics announces alpha3 trial-in-progress poster presentation at ash annual meeting

South san francisco, calif., nov. 03, 2025 (globe newswire) -- allogene therapeutics, inc. (nasdaq: allo), a clinical-stage biotechnology company pioneering the development of allogeneic car t (allocar t™) products for cancer and autoimmune disease, today announced that a trial-in-progress (tip) poster highlighting the pivotal phase 2 alpha3 trial evaluating cemacabtagene ansegedleucel (cema-cel) will be presented at the 2025 american society of hematology (ash) annual meeting in orlando, florida.
ASH Ratings Summary
ASH Quant Ranking